Syndax Pharmaceuticals, Inc. Deferred Offering Costs
Syndax Pharmaceuticals, Inc. (SNDX) had Deferred Offering Costs of $0 as of 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2017-11-08
- 2017-09-30: Deferred Offering Costs $0.00.
- 2017-06-30: Deferred Offering Costs $0.00.
- 2017-03-31: Deferred Offering Costs $100.00K.
- 2016-09-30: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-08 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-10 |
| 2017-03-31 | $100.00K 10-Q · filed 2017-05-09 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-10 |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-09 |
| 2014-09-30 | $4.30M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |